Internal Med

Your Article Summary

See Latest Articles

The use of triiodothyronine as an augmentation agent in treatment-resistant bipolar II and bipolar disorder NOS
Journal of Affective Disorders, 06/22/09

Kelly T et al. - A high percentage of bipolar II and bipolar NOS patients with treatment resistant depression improved on T3. Despite the use of higher than usual doses in many of the patients, the medication was well tolerated. Augmentation with supraphysiologic doses of T3 should be considered in cases of treatment resistant bipolar depression.

• Retrospective chart review of patients treated in a private clinic between 2002 and 2006.
• The charts of 125 patients with bipolar II disorder and 34 patients with bipolar disorder NOS were reviewed.

• Patients had been unsuccessfully treated with an average of 14 other medications before starting T3.
• At an average dose of 90.4 mcg (range 13 mcg–188 mcg) the medication was well tolerated.
• None of the patients experienced a switch into hypomania, and only 16 discontinued due to side effects.
• Improvement was experienced by 84%, and 33% experienced full remission.

Today in Psychiatry...keeping you current

Receive free subspecialty "5-minute updates" via email

Escitalopram and Venlafaxine for the Prophylaxis of Migraine Headache Without Mood Disorders
Clinical Neuropharmacology, 10/02/09

Estimation of clonazepam abuse liability: a new method using a reimbursed drug database
International Clinical Psychopharmacology, 10/20/09

Asenapine versus olanzapine in acute mania: a double-blind extension study
Bipolar Disorders, 10/22/09

See All of Psychiatry